Does State Medicaid Cover Ozempic?

How Medicaid Drug Coverage Works for GLP-1 Agonists

Each state administers its own Medicaid program under federal guidelines, which means drug formularies are not uniform. The Medicaid Drug Rebate Program requires participating manufacturers to provide rebates to state Medicaid agencies, and in return states generally must cover FDA-approved drugs from those manufacturers. Novo Nordisk participates in this program, so states cannot categorically exclude Ozempic from coverage for its FDA-approved indication of type 2 diabetes.

That legal requirement does not prevent states from imposing utilization controls. Prior authorization, step therapy, quantity limits, and preferred-drug-list placement are all permitted under federal Medicaid law (42 U.S.C. § 1396r-8). The practical result: a Medicaid beneficiary in New York may face different hurdles than one in Texas, even though both states nominally "cover" the same medication.

States that manage Medicaid through managed care organizations (MCOs) add another layer. Over 70% of Medicaid enrollees are in managed care plans, according to CMS data, and each MCO may maintain its own formulary within state guidelines. A single state could have three or four MCOs, each with different tier placement for semaglutide.

Ozempic Coverage for Type 2 Diabetes on Medicaid

Coverage for the on-label indication is close to universal. Because semaglutide 0.5 mg, 1 mg, and 2 mg pens carry FDA approval for glycemic control in adults with type 2 diabetes, and because Novo Nordisk participates in the federal rebate program, every state must provide some pathway to access. The SUSTAIN clinical trial program demonstrated that semaglutide 0.5 mg and 1 mg reduced HbA1c by 1.0% to 1.8% compared with 0.4% to 0.9% for comparators, data that supports medical-necessity arguments in prior-authorization requests.

However, "covered" does not mean "easy to get." A 2023 analysis published in JAMA Network Open found that prior authorization for GLP-1 receptor agonists in Medicaid was associated with lower utilization and treatment delays averaging 14 to 30 days. States typically require the prescriber to document:

• A confirmed HbA1c of 7.0% or higher (some states set the bar at 8.0%)
• Failure or intolerance of metformin at a maximally tolerated dose
• Body mass index or weight documentation
• Prescriber specialty (endocrinologist, diabetologist, or primary care)

The American Diabetes Association Standards of Care (2024) recommend GLP-1 receptor agonists as second-line therapy after metformin, or as first-line therapy in patients with established atherosclerotic cardiovascular disease. This guideline language can strengthen a prior-authorization submission.

Why Obesity-Only Coverage Remains Limited

Ozempic is prescribed off-label for weight loss, but the drug does not carry an FDA obesity indication. That distinction matters for Medicaid. Wegovy (semaglutide 2.4 mg) holds the FDA-approved obesity indication, yet a KFF analysis found that fewer than half of state Medicaid programs cover any anti-obesity medication.

States that do exclude obesity coverage often cite cost. At a list price of $998 per month, covering semaglutide for weight management across the Medicaid population would represent a significant budget line item. The Congressional Budget Office estimated that broad Medicaid coverage of GLP-1 agonists for obesity could increase federal Medicaid spending by billions annually.

Some states have begun to change course. North Carolina's Medicaid program added anti-obesity medication coverage in 2024. A small number of other states, including New York, have pilot programs or waivers under consideration. The trajectory is toward broader coverage, but the current field remains patchy, and beneficiaries seeking Ozempic specifically for weight loss in most states will receive a denial.

Prior-Authorization Requirements by State

Prior authorization is the most common barrier. Nearly every state Medicaid program requires PA for Ozempic, though the specific criteria differ. A 2022 study in Diabetes Care documented that Medicaid prior-authorization policies for GLP-1 receptor agonists correlate with racial and geographic disparities in prescribing rates. Black and Hispanic beneficiaries were 30% to 40% less likely to receive a GLP-1 agonist than White beneficiaries within the same state, partly because of the administrative burden PA imposes on safety-net clinics.

Common PA criteria across states include:

Diagnosis documentation. The prescriber must submit an ICD-10 code for type 2 diabetes (E11.x). Off-label weight-loss requests (E66.01) are rejected in most states unless the program explicitly covers anti-obesity medications.

Step-therapy completion. Many states require a documented trial of metformin (minimum 500 mg twice daily for 90 days) and sometimes a second agent such as a sulfonylurea or SGLT2 inhibitor. The Endocrine Society Clinical Practice Guideline on Pharmacological Management of Obesity supports GLP-1 agonist use after lifestyle intervention, but state Medicaid formularies may not align with these recommendations.

Prescriber restrictions. A few states limit initial prescriptions to endocrinologists or diabetologists, although most accept primary care prescribers with supporting lab work.

Renewal criteria. States frequently require evidence of HbA1c reduction (typically 0.5% or greater) at 6 or 12 months for continued authorization.

The Medicaid and CHIP Payment and Access Commission (MACPAC) has noted that utilization management tools like PA can both control costs and limit medically necessary access. Clinicians should document clinical rationale thoroughly and include relevant trial data in every submission.

Step-Therapy Requirements

Step therapy mandates that a patient try and fail one or more lower-cost medications before the insurer will cover a more expensive drug. For Ozempic on Medicaid, step therapy commonly involves:

1. Metformin at maximally tolerated dose for at least 90 days
2. A sulfonylurea (glipizide, glimepiride) or an SGLT2 inhibitor (empagliflozin, dapagliflozin) for 60 to 90 days
3. Another GLP-1 receptor agonist such as dulaglutide (Trulicity) or liraglutide (Victoza) that may be on the state's preferred drug list

The rationale for this sequencing comes partly from the ADA/EASD Consensus Report on the Management of Type 2 Diabetes, which recommends metformin as initial pharmacotherapy. But the same consensus also recognizes that GLP-1 receptor agonists may be appropriate as initial injectable therapy in patients with HbA1c more than 1.5% above target, or in patients with atherosclerotic cardiovascular disease or chronic kidney disease.

If a patient has a documented contraindication to metformin (eGFR <30 mL/min, lactic acidosis history, severe gastrointestinal intolerance), step-therapy requirements should be waived. Prescribers should submit lab documentation and clinical notes explicitly addressing why each step was clinically inappropriate. A 2021 analysis in the Annals of Internal Medicine found that step-therapy overrides were granted in roughly 60% to 70% of cases when adequate clinical documentation accompanied the request.

How to Appeal a Medicaid Denial of Ozempic

Every state Medicaid program must provide a fair-hearing process when a claim is denied. The CMS State Medicaid Manual (Section 2902) outlines the federal minimum standards for these hearings. Here is the general process:

Step 1: Request the denial letter. The MCO or state agency must provide a written notice explaining the reason for denial, the regulation or policy cited, and the deadline to file an appeal (typically 30 to 90 days depending on the state).

Step 2: File a plan-level appeal. Most MCOs require an internal appeal before the state fair hearing. The prescriber should submit a letter of medical necessity that includes the patient's HbA1c history, prior medication trials and their outcomes, relevant comorbidities (cardiovascular disease, chronic kidney disease, non-alcoholic fatty liver disease), and citations to clinical guidelines.

Step 3: Request a state fair hearing. If the MCO upholds the denial, the beneficiary (or their authorized representative) can request a hearing before an administrative law judge. The National Health Law Program recommends including peer-reviewed evidence and guideline citations in the hearing packet.

Step 4: Cite clinical evidence. The SUSTAIN trial program, specifically SUSTAIN-6 (N=3,297), demonstrated a 26% reduction in major adverse cardiovascular events with semaglutide vs. Placebo, making a strong case for medical necessity in patients with cardiovascular risk. The SELECT trial (N=17,604) further showed a 20% reduction in MACE with semaglutide 2.4 mg in patients with overweight or obesity and established cardiovascular disease.

Success rates for Medicaid drug appeals vary, but prescribers who submit complete documentation with guideline references report approval in the majority of cases.

Can You Use the Manufacturer Savings Card With Medicaid?

No. Novo Nordisk's Ozempic savings card explicitly excludes patients enrolled in any federal or state-funded healthcare program, including Medicaid, Medicare, TRICARE, and the VA. This restriction exists because of the Anti-Kickback Statute (42 U.S.C. § 1320a-7b) and the OIG guidance on manufacturer copay coupons. Using a manufacturer coupon to reduce out-of-pocket costs for a federally funded beneficiary is considered a potential inducement that could increase program spending.

Medicaid beneficiaries who cannot access Ozempic may have alternatives:

• Novo Nordisk Patient Assistance Program (PAP). Uninsured patients (not Medicaid-enrolled) with household income below 400% of the federal poverty level may qualify for free medication through Novo Nordisk's PAP.
• State pharmaceutical assistance programs. Some states operate supplemental programs that fill coverage gaps.
• 340B Program. Federally qualified health centers and qualifying hospitals purchase drugs at discounted rates through the 340B Drug Pricing Program, and those savings can be passed to patients.

Formulary Tier Placement Across States

When Ozempic is on a state Medicaid formulary, it typically sits on a non-preferred or specialty tier, meaning higher cost-sharing (if applicable) and mandatory prior authorization. Preferred GLP-1 receptor agonists on many state Medicaid formularies include dulaglutide (Trulicity) or liraglutide (Victoza), which carry lower net costs to states after rebate negotiations.

A 2024 study in Health Affairs analyzed Medicaid preferred drug lists across 50 states and found that only 18 states listed semaglutide injection as a preferred agent, while 32 states placed it on the non-preferred tier, requiring prescribers to demonstrate why a preferred-tier alternative was inadequate. The practical effect: prescribers in non-preferred states must include documentation of a failed trial on the preferred GLP-1 agonist before semaglutide will be authorized.

Checking your specific state's formulary is straightforward. Each state Medicaid agency publishes its preferred drug list (PDL) online. Search "[your state] Medicaid preferred drug list" to find the current document, or call the number on the back of your Medicaid card to ask about Ozempic's tier placement directly.

What to Do If Your State Does Not Cover Ozempic

If Ozempic is denied and appeals are exhausted, several clinical alternatives exist. For type 2 diabetes, dulaglutide (Trulicity) demonstrated HbA1c reductions of 0.78% to 1.64% across the AWARD trial program. Liraglutide (Victoza) reduced HbA1c by 1.1% to 1.3% in the LEAD trials and sits on more state Medicaid formularies as a preferred agent.

For patients whose primary goal is weight reduction, oral semaglutide (Rybelsus) may have different formulary placement than injectable Ozempic in some states. The PIONEER trials showed oral semaglutide 14 mg reduced HbA1c by 1.3% and body weight by 4.4 kg at 26 weeks.

Patients should work with their prescribers to identify the GLP-1 agonist most likely to be covered by their specific state Medicaid plan, then pursue prior authorization for that agent first. If the preferred agent fails to produce adequate glycemic control after 90 days, that documented failure becomes the strongest evidence for a non-preferred drug exception request for Ozempic.